MCK at a glance
McKesson Corporation (MCK, SEC CIK 927653) filed its latest 10-K annual report on May 8, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended March 31, 2026 (FY2026), McKesson Corporation (MCK) reported revenue of $403.4 billion (up 12.4% from FY2025) and net income of $4.8 billion. Diluted EPS was $38.38.
- As of September 30, 2026, 59 institutional investment managers tracked by SignalX reported holding McKesson Corporation (MCK) shares worth $38.9 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Fraga Francisco on November 5, 2026 of 650 shares at $1102.96 per share.
- In the last 90 days, MCK insiders reported 0 open-market purchases ($0) and 4 open-market sales ($2.2M) on Form 4, a net sale of $2.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2026
- $403.4B
- +12.4% vs prior year
- Insiders · 90 days
- 0 buys · 4 sells
- Net −$2.2M
- 13F holders
- 59 funds
- $38.9B · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- No material changes to 10-K risk factors during the quarter
- Carried-forward risks remain unchanged, including regulatory, legal, operational, competitive, market, liquidity, debt, currency and concentration exposures
Management Discussion & Analysis
- Revenue $110,957M, up 8% YoY from $103,150M, driven by pharmaceutical volumes and specialty pharmaceuticals
- Gross margin 3.57% vs 3.43% YoY, operating-expense ratio 2.12% vs 2.07%
- Best segment Oncology & Multispecialty: revenue $14,980M, up 24%; worst margin trend Medical-Surgical Solutions: 5.30% vs 7.47%
- Operating cash flow $2,850M vs $1,502M; cash balance $6,619M vs $4,068M at March 31
- Capital deployment: $3,400M repurchases and $198M dividends; regulatory uncertainty, drug pricing, and opioid liabilities remained headwinds
AI summary of the MCK 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Preliminary quarterly results for quarter ended September 30, 2026
- Results available in Exhibit 99.1 for detailed financial metrics and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $111.0B, up 8%, with adjusted EPS $11.68, up 18%, signaling strong operating momentum
- Free cash flow $2.9B and $3.6B returned to shareholders year-to-date, including $3.4B in repurchases
Item 7.01: Regulation FD Disclosure
- Proposed acquisition of Option Care Health announced jointly by McKesson, CD&R and Option Care Health
- Transaction details and strategic rationale contained in Exhibit 99.1 and the referenced company websites
Item EX-99.1: Item EX-99.1
- McKesson investing approximately $1.4B for a 49% minority stake in Option Care Health, expanding specialty-care and home-infusion exposure
- CD&R will control approximately 51%, with Option Care remaining separately managed and privately held after closing
Item 7.01: Regulation FD Disclosure
- Cybersecurity incident discovered August 25, 2026, affecting McKesson information systems
- Investigation remains in early stages, creating ongoing uncertainty around scope and operational impact
AI summaries of MCK 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for MCK
Don't miss the next MCK filing
- Alerts as it files. A push when MCK files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut MCK, by share count.
- Ask anything. An AI agent that reads every MCK filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Fraga Francisco | Sell | Nov 5, 2026 | 650 | $1102.96 |
| Fraga Francisco | Sell | Nov 4, 2026 | 600 | $1050.00 |
| Fraga Francisco | D | Nov 3, 2026 | 398 | - |
| Fraga Francisco | M | Nov 3, 2026 | 398 | - |
| Fraga Francisco | F | Nov 3, 2026 | 157 | $999.62 |
| Fraga Francisco | Sell | Oct 15, 2026 | 800.491 | $995.80 |
| Rutledge Napoleon B JR | Sell | Sep 8, 2026 | 111 | $891.45 |
| Lerman Bradley E | Sell | Aug 10, 2026 | 301 | $892.33 |
Financial SummaryXBRL
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $359.1B | $403.4B |
| Gross Profit | - | $13.3B | $14.6B |
| Operating Income | - | $4.4B | $6.2B |
| Net Income | - | $3.3B | $4.8B |
| Gross Margin | - | 3.7% | 3.6% |
| Op. Margin | - | 1.2% | 1.5% |
| Net Margin | - | 0.9% | 1.2% |
| Balance Sheet | |||
| Total Assets | $67.4B | $75.1B | $82.3B |
| Equity | - | -$2.1B | -$2.2B |
| ROE | - | -158.9% | -219.2% |
| Per Share | |||
| EPS | - | $25.72 | $38.38 |
| Cash Flow | |||
| Operating CF | - | $6.1B | $6.2B |
| CapEx | $431.0M | $537.0M | $436.0M |
Source: XBRL data in McKesson Corporation (MCK)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate MCK share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 59 | $38.88B |
| Q2 2026 | 58 | $38.21B |
| Q1 2026 | 59 | $44.80B |
| Q4 2025 | 56 | $40.00B |
| Q3 2025 | 55 | $41.74B |
| Q2 2025 | 53 | $38.29B |
| Q1 2025 | 52 | $26.32B |
| Q4 2024 | 45 | $17.85B |
- AQR Capital Management+289.9K (+33%)
- Ameriprise Financial+237.4K (+141%)
- Citigroup+192.0K (+122%)
- D.E. Shaw & Co+19.2K (+4%)
- Millennium Management+19.1K (+19%)
- Morgan Stanley−1.49M (-28%)
- BlackRock−705.1K (-7%)
- JPMorgan Chase & Co−464.1K (-27%)
- Goldman Sachs Group−309.7K (-23%)
- Citadel Advisors LLC−242.6K (-53%)
- FMR LLC (Fidelity)−2.13M
- Equitable Holdings Inc−3.5K
- Blackstone Group−1.1K
Source: 13F-HR filings on SEC EDGAR (aggregated from 437 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
MCK filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 6, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 19, 2026 | - | - | - |
| 8-K | Oct 6, 2026 | - | Analysis | - |
| 4 | Sep 10, 2026 | - | - | - |
| 8-K | Aug 28, 2026 | - | Analysis | - |
| 4 | Aug 11, 2026 | - | - | - |
| 4 | Aug 11, 2026 | - | - | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 8-K | Jul 24, 2026 | - | Analysis | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 23, 2026 | - | - | - |
| 4 | Jul 8, 2026 | - | - | - |
| 8-K | Jul 1, 2026 | - | Analysis | - |
Related Health Care companies
- CAH · Cardinal HealthWholesale-Drugs, Proprietaries & Druggists' Sundries
- COR · CencoraWholesale-Drugs, Proprietaries & Druggists' Sundries
- HLF · HERBALIFE LTD.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- NUS · NU SKIN ENTERPRISES, INC.Wholesale-Drugs, Proprietaries & Druggists' Sundries
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
MCK SEC filings: frequently asked questions
Are MCK insiders buying or selling?
In the last 90 days, McKesson Corporation (MCK) officers, directors and 10% owners reported no open-market purchases and 4 open-market sales worth $2.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold MCK stock?
As of September 30, 2026, the largest McKesson Corporation (MCK) holders among the 13F filers tracked by SignalX were BlackRock ($8.6 billion), Vanguard Capital Management LLC ($6.5 billion), State Street Corp ($4.7 billion), Morgan Stanley ($3.3 billion), Franklin Resources ($3.1 billion). 13F-HR reports are filed up to 45 days after each quarter ends.
What was MCK's revenue in fiscal year 2026?
For the fiscal year ended March 31, 2026 (FY2026), McKesson Corporation (MCK) reported revenue of $403.4 billion (up 12.4% from FY2025) and net income of $4.8 billion. Diluted EPS was $38.38. The figures come from the XBRL data in the 10-K.
What did MCK report in its latest 8-K?
McKesson Corporation (MCK) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Preliminary quarterly results for quarter ended September 30, 2026.
What are the latest MCK SEC filings?
McKesson Corporation (MCK) filed its latest 10-K annual report on May 8, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 6, 2026.
What is MCK's SEC CIK number?
McKesson Corporation (MCK)'s SEC Central Index Key (CIK) is 927653. EDGAR lists every MCK filing under that number.
Ask anything about MCK
The research agent reads MCK's filings, financials, insider trades and 13F holders, then answers with sources.